scholarly journals Variability of crossing phase in older people with Parkinson’s disease is dependent of obstacle height

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Lucas Simieli ◽  
Fabio Augusto Barbieri ◽  
Diego Orcioli-Silva ◽  
Ellen Lirani-Silva ◽  
Victor Spiandor Beretta ◽  
...  
2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Lucas Simieli ◽  
Fabio Augusto Barbieri ◽  
Diego Orcioli-Silva ◽  
Ellen Lirani-Silva ◽  
Victor Spiandor Beretta ◽  
...  

Author(s):  
John V. Hindle ◽  
Sion Jones ◽  
Glesni Davies

Parkinson’s disease (PD) is a progressive neurodegenerative condition characterized clinically by fatiguable bradykinesia, rigidity and tremor and pathologically by deposition of Lewy bodies and cell loss in the substantia nigra and other brain regions. Parkinsonism is the term used to describe the clinical features of conditions resembling PD. Their management requires specialist assessment and a multidisciplinary approach. Levodopa remains the mainstay of treatment for PD. Although other treatments are used, older people are more sensitive to their side effects. Non-motor symptoms, particularly neuropsychiatric problems, significantly impact quality of life and need special consideration in older people. Towards the later stage of the disease, management can be complex, and should involve advanced care planning.


2015 ◽  
Vol 5 (1) ◽  
pp. 105-116 ◽  
Author(s):  
Matthew A.D. Brodie ◽  
Roger T. Dean ◽  
Tim R. Beijer ◽  
Colleen G. Canning ◽  
Stuart T. Smith ◽  
...  

BMC Neurology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Roberta Bevilacqua ◽  
Elvira Maranesi ◽  
Mirko Di Rosa ◽  
Riccardo Luzi ◽  
Elisa Casoni ◽  
...  

1997 ◽  
Vol 42 (5) ◽  
pp. 147-150 ◽  
Author(s):  
C.T.C. Lien ◽  
W.J. Mutch

Parkinson's disease is characterised by a variable combination of tremor, rigidity, bradykinesia and impaired righting reflexes. The cumulative life-time risk is one in 40. Levodopa remains the single most effective treatment in older patients, and the minimum dose to achieve maxiumu functional benefit should be employed. When fluctuations occur, controlled release preparations and selegiline can improve function. Oral dopamine agonists have a role but the combined side effect profile with levodopa should be monitored. COMT inhibitors have recently become available. Subcutaneous apomorphine can be helpful when “on-off phenomema are marked. The concept of neuroprotection continues to be debated. Surgery is an option for fitter older people but neurotransplantation remains essentially a research tool.


2019 ◽  
Vol 128 ◽  
pp. 110766 ◽  
Author(s):  
Anna Picca ◽  
Riccardo Calvani ◽  
Giovanni Landi ◽  
Federico Marini ◽  
Alessandra Biancolillo ◽  
...  

Medicine ◽  
2021 ◽  
Vol 49 (1) ◽  
pp. 56-61
Author(s):  
Alison Bamford ◽  
Emily J. Henderson

GeroScience ◽  
2020 ◽  
Vol 42 (5) ◽  
pp. 1323-1334 ◽  
Author(s):  
Riccardo Calvani ◽  
Anna Picca ◽  
Giovanni Landi ◽  
Federico Marini ◽  
Alessandra Biancolillo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document